Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 2
1996 pubmed

Role of the new growth hormone-releasing secretagogues in the diagnosis of some hypothalamopituitary pathologies.

Casanueva. F F FF; Micic. D D; Pombo. M M; Leal. A A; Bokser. L L; Zugaza. J L JL; Dieguez. C C

Key Findings

  • GHRP‑6‑induced GH release is blocked in adults and children with hypothalamic‑pituitary disconnection, indicating its primary action is at the hypothalamic level.
  • The synergistic GH surge seen with GHRH + GHRP‑6 in normal adults is absent in patients with a broken hypothalamic‑pituitary link.
  • A combined GHRH + GHRP‑6 test may serve as a diagnostic tool for GH deficiency caused by interruption of the hypothalamic‑pituitary connection.

Practical Outcomes

  • For most biohackers, this research doesn’t change dosing or performance protocols, but it clarifies that GHRP‑6 works via the brain’s GH‑regulating system. If you’re using GHRP‑6 to boost GH, a normal response suggests an intact hypothalamic‑pituitary axis. The main takeaway is its diagnostic potential, not a new therapeutic regimen.

Summary

The study shows that the peptide GHRP‑6 makes the brain release growth hormone, but this effect disappears in people whose hypothalamus‑pituitary connection is broken. When GHRP‑6 is given together with GHRH, healthy adults get a big boost in GH, while those with a disrupted connection do not. This suggests a combined GHRH + GHRP‑6 test could help diagnose certain GH‑deficiency conditions.

Abstract

Growth hormone (GH)-releasing hormone (GHRH) and somatostatin have a dominant role in regulating GH secretion. However, results of studies using the new class of GH secretogogues, particularly GHRP-6, indicate that there may also be other, as yet undefined, hypothalamic mechanisms involved. Studies in adults with hypothalamopituitary disconnection (functional pituitary stalk transection), show GHRP-6-mediated GH release to be completely blocked, indicating a main action at the hypothalamic rather than the pituitary level. The synergistic effect of GHRH plus GHRP-6 administration on GH release seen in normal adults (and virtually unaffected by age, obesity, or sex) is also absent in these patients, providing further support for this conclusion. Studies of the effects of GHRP-6 in children with GH deficiency due to perinatal pituitary stalk transection have produced similar findings. It is suggested that the combined GHRH plus GHRH-6 test should be a promising tool for diagnosing GH deficiency states in both children and adults, and may identify a subgroup of patients with GH deficiency caused by interruption of the hypothalamopituitary connection.

Study Information

Provider

pubmed

Year

1996

DOI

10.1016/s0026-0495(96)90105-5